Moderna announced the change Wednesday, about a week after revealing that the FDA's vaccine chief was refusing to review the new vaccine, made with Nobel Prize-winning mRNA technology. The dispute centred over a 40,000-person clinical trial that concluded Moderna's new vaccine was more effective in adults age 50 and older than one of the standard flu shots used today. In the FDA's rare "refusal to file" letter, vaccine director Dr. Vinay Prasad faulted the trial for not including another brand specifically ...

The Food and Drug Administration has reversed its decision not to review a new flu vaccine from Moderna, the pharmaceutical company said Wednesday.Last week, the FDA sent a missive to Moderna refusing to review its new shot, saying its application did not contain adequate research – leaving the company’s president Dr. Stephen Hoge in “complete shock.”Moderna’s flu vaccine will not be reviewed by the FDA. Rawf8 – stock.adobe.comIn an exclusive interview with The Post, Hoge said he was “completely surprised a ...